Pharmalittle: FDA extends probe into AstraZeneca Covid-19 vaccine – STAT

Good morning, everyone, and how are you today? We are just fine, thank you, courtesy of blue skies and deliciously cool breezes wafting about the Pharmalot campus. Moreover, our rambunctious official mascot is now happily snoozing on the floor, providing an opportunity to brew cups of stimulation and attend to our to-do list. Nothing like a quiet pup when there is work to be done. Speaking of which, here are a few tidbits to get you started. We hope your day is simply smashing — a little optimism never hurts — and you stay safe. …

The Food and Drug Administration has broadened its investigation of a serious illness in AstraZeneca’s (AZN) Covid-19 vaccine study and will look at data from earlier trials of similar vaccines developed by the same scientists, Reuters reports. The large, late-stage U.S. trial has been on hold since Sept. 6, after a study participant in the U.K. fell ill with what was believed to be a rare spinal inflammatory disorder called transverse myelitis. The requested data was expected to arrive this week, after which the FDA would need time to analyze it.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Read the original article

Author: The Covid-19 Channel